Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys

Castellanos, Alejandro; Arévalo‐Herrera, Myriam; Restrepo, Nora; Gulloso, Leonel; Corradin, Giampietro; Herrera, Sócrates

doi:10.1590/s0074-02762007005000047

Cited by 25 publications

(18 citation statements)

References 19 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, 63 Thailand sequences from GenBank were included in the amino acid alignment. The N-terminal region (209-256aa), which has been proved to be immunogenic and to provide partial protection in Aotus monkeys [24] was highly conserved with only three amino acid substitutions in positions 216 (R/K), 219 (H/Q) and 229 (G/K). In general, more diversity was found in Thailand (h = 34, π = 0.007 ± 0.00029 and Hd = 0.961 ± 0.01) (Table 2) compared to Peru (h = 7, π = 0.00235 ± 0.00012 and Hd = 0.641 ± 0.026) and according to the Dn-Ds test, regions II and III of Pvtrap were under positive selection (Table 3).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Genetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax

Chenet

Tapia

Escalante

et al. 2012

Malar J

View full text Add to dashboard Cite

BackgroundA major concern in malaria vaccine development is genetic polymorphisms typically observed among Plasmodium isolates in different geographical areas across the world. Highly polymorphic regions have been observed in Plasmodium falciparum and Plasmodium vivax antigenic surface proteins such as Circumsporozoite protein (CSP), Duffy-binding protein (DBP), Merozoite surface protein-1 (MSP-1), Apical membrane antigen-1 (AMA-1) and Thrombospondin related anonymous protein (TRAP).MethodsGenetic variability was assessed in important polymorphic regions of various vaccine candidate antigens in P. vivax among 106 isolates from the Amazon Region of Loreto, Peru. In addition, genetic diversity determined in Peruvian isolates was compared to population studies from various geographical locations worldwide.ResultsThe structured diversity found in P. vivax populations did not show a geographic pattern and haplotypes from all gene candidates were distributed worldwide. In addition, evidence of balancing selection was found in polymorphic regions of the trap, dbp and ama-1 genes.ConclusionsIt is important to have a good representation of the haplotypes circulating worldwide when implementing a vaccine, regardless of the geographic region of deployment since selective pressure plays an important role in structuring antigen diversity.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The potential role of TRAP as a malaria vaccine candidate has been tested in mice and monkeys, inducing high levels of specific antibodies [23]. Furthermore, a synthetic peptide-derived from a conserved region of the TRAP protein located in the N-terminal, proved to be immunogenic and provided partial protection in Aotus monkeys [1,24]. …”

Section: Introductionmentioning

confidence: 99%

Genetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax

Chenet

Tapia

Escalante

et al. 2012

Malar J

View full text Add to dashboard Cite

show abstract

“…More recently, LSP formulated with Montanide ISA 720 was tested in BALB/c mice and Aotus monkeys and it resulted in specific antibody responses in both animal species. Although Aotus monkeys showed partial protection against challenge with P. vivax sporozoites, no further studies have been reported with this or other SSP2/TRAP constructs (Castellanos et al 2007). …”

Section: Preclinical Studies Using P Vivax Subunit Vaccines: Immunogmentioning

confidence: 88%

“…It was first cloned in 1997 (Templeton & Kaslow 1997), and its immunogenicity and protective efficacy in rodents and Aotus monkeys has been tested (Castellanos et al 2007). It has also been shown to be effective in mice as a DNA vaccine (Rogers et al 1999) (see Preclinical studies using P. vivax subunit vaccines: immunogenicity and protective efficacy ).…”

Section: Pre-erythrocytic Vaccinesmentioning

confidence: 99%

Platform for Plasmodium vivax vaccine discovery and development

Valencia

Rodríguez

Acero

et al. 2011

Mem. Inst. Oswaldo Cruz

Self Cite

View full text Add to dashboard Cite

Plasmodium vivax is the most prevalent malaria parasite on the American continent. It generates a global burden of 80–100 million cases annually and represents a tremendous public health problem, particularly in the American and Asian continents. A malaria vaccine would be considered the most cost-effective measure against this vector-borne disease and it would contribute to a reduction in malaria cases and to eventual eradication. Although significant progress has been achieved in the search for Plasmodium falciparum antigens that could be used in a vaccine, limited progress has been made in the search for P. vivax components that might be eligible for vaccine development. This is primarily due to the lack of in vitro cultures to serve as an antigen source and to inadequate funding. While the most advanced P. falciparum vaccine candidate is currently being tested in Phase III trials in Africa, the most advanced P. vivax candidates have only advanced to Phase I trials. Herein, we describe the overall strategy and progress in P. vivax vaccine research, from antigen discovery to preclinical and clinical development and we discuss the regional potential of Latin America to develop a comprehensive platform for vaccine development.

show abstract

“…However, a host of additional P.vivax proteins are currently under investigation as potential vaccine candidates, including PvDBP [38], PvTRAP [186], PvMSP-1 [187], PvAMA-1 [188]; and the transmission blocking candidate, Pvs28 [38]. Additional antigens identified as potential P.vivax vaccine candidates include PvMSP3, PvMSP4, PvMSP5 and PvRBPs I and II [38].…”

Section: Plasmodium Vivaxmentioning

confidence: 99%